APELLIS PHARMACTDL (Germany) Performance
| 1JK Stock | EUR 31.28 0.82 2.55% |
On a scale of 0 to 100, APELLIS PHARMACTDL holds a performance score of 4. The firm shows a Beta (market volatility) of 0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, APELLIS PHARMACTDL's returns are expected to increase less than the market. However, during the bear market, the loss of holding APELLIS PHARMACTDL is expected to be smaller as well. Please check APELLIS PHARMACTDL's semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether APELLIS PHARMACTDL's price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in APELLIS PHARMACTDL 0001 are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, APELLIS PHARMACTDL reported solid returns over the last few months and may actually be approaching a breakup point. ...more
APELLIS |
APELLIS PHARMACTDL Relative Risk vs. Return Landscape
If you would invest 2,850 in APELLIS PHARMACTDL 0001 on September 21, 2024 and sell it today you would earn a total of 278.00 from holding APELLIS PHARMACTDL 0001 or generate 9.75% return on investment over 90 days. APELLIS PHARMACTDL 0001 is currently producing 0.2212% returns and takes up 4.0483% volatility of returns over 90 trading days. Put another way, 36% of traded stocks are less volatile than APELLIS, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
APELLIS PHARMACTDL Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for APELLIS PHARMACTDL's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as APELLIS PHARMACTDL 0001, and traders can use it to determine the average amount a APELLIS PHARMACTDL's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0547
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 1JK | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.05 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average APELLIS PHARMACTDL is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of APELLIS PHARMACTDL by adding it to a well-diversified portfolio.
APELLIS PHARMACTDL Fundamentals Growth
APELLIS Stock prices reflect investors' perceptions of the future prospects and financial health of APELLIS PHARMACTDL, and APELLIS PHARMACTDL fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on APELLIS Stock performance.
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Revenue | 113.05 M | |||
| EBITDA | (518.43 M) | |||
| Cash And Equivalents | 599.01 M | |||
| Cash Per Share | 6.89 X | |||
| Total Debt | 409.63 M | |||
| Debt To Equity | 7.94 % | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (239.85 M) | |||
| Earnings Per Share | (7.48) X | |||
About APELLIS PHARMACTDL Performance
By analyzing APELLIS PHARMACTDL's fundamental ratios, stakeholders can gain valuable insights into APELLIS PHARMACTDL's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if APELLIS PHARMACTDL has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if APELLIS PHARMACTDL has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.Things to note about APELLIS PHARMACTDL 0001 performance evaluation
Checking the ongoing alerts about APELLIS PHARMACTDL for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for APELLIS PHARMACTDL 0001 help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| APELLIS PHARMACTDL had very high historical volatility over the last 90 days | |
| The company reported the revenue of 113.05 M. Net Loss for the year was (460.28 M) with loss before overhead, payroll, taxes, and interest of (253.92 M). | |
| APELLIS PHARMACTDL 0001 has accumulated about 599.01 M in cash with (239.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.89. | |
| Over 89.0% of the company shares are owned by institutions such as pension funds |
- Analyzing APELLIS PHARMACTDL's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether APELLIS PHARMACTDL's stock is overvalued or undervalued compared to its peers.
- Examining APELLIS PHARMACTDL's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating APELLIS PHARMACTDL's management team can have a significant impact on its success or failure. Reviewing the track record and experience of APELLIS PHARMACTDL's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of APELLIS PHARMACTDL's stock. These opinions can provide insight into APELLIS PHARMACTDL's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for APELLIS Stock analysis
When running APELLIS PHARMACTDL's price analysis, check to measure APELLIS PHARMACTDL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy APELLIS PHARMACTDL is operating at the current time. Most of APELLIS PHARMACTDL's value examination focuses on studying past and present price action to predict the probability of APELLIS PHARMACTDL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move APELLIS PHARMACTDL's price. Additionally, you may evaluate how the addition of APELLIS PHARMACTDL to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |